Regulation of Long Non-coding RNAs and MicroRNAs in Heart Disease: Insight Into Mechanisms and Therapeutic Approaches

Collins, Lucy; Binder, Pablo; Chen, Hongshan; Wang, Xin

doi:10.3389/fphys.2020.00798

Cited by 24 publications

(22 citation statements)

References 182 publications

(201 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…MicroRNAs (miRNAs) are a family of small single-stranded noncoding RNAs of approximately 19-24 nucleotides in length that have multiple functions in cancer, nervous development, metabolic disorders such as obesity, and cardiovascular diseases [ 5 ]. Mature miRNAs align and bind to the 3′-UTR sequences of their target mRNAs, and they are integrated into the RNA-induced silencing complex (RISC), leading to target mRNA degradation [ 6 ].…”

Section: Introductionmentioning

confidence: 99%

miR-340-5p Mediates Cardiomyocyte Oxidative Stress in Diabetes-Induced Cardiac Dysfunction by Targeting Mcl-1

Zhu

Yang

Zhou

et al. 2022

Oxidative Medicine and Cellular Longevity

View full text Add to dashboard Cite

Diabetic cardiomyopathy (DCM) is initially characterized by early diastolic dysfunction, left ventricular remodeling, hypertrophy, and myocardial fibrosis, and it is eventually characterized by clinical heart failure. MicroRNAs (miRNAs), endogenous small noncoding RNAs, play significant roles in diabetes mellitus (DM). However, it is still largely unknown about the mechanism that links miRNAs and the development of DCM. Here, we aimed to elucidate the mechanism underlying the potential role of microRNA-340-5p in DCM in db/db mouse, which is a commonly used model of type 2 DM and diabetic complications that lead to heart failure. We first demonstrated that miR-340-5p expression was dramatically increased in heart tissues of mice and cardiomyocytes under diabetic conditions. Overexpression of miR-340-5p exacerbated DCM, which was reflected by extensive myocardial fibrosis and more serious dysfunction in db/db mice as represented by increased apoptotic cardiomyocytes, elevated ROS production, and impaired mitochondrial function. Inhibition of miR-340-5p by a tough decoy (TUD) vector was beneficial for preventing ROS production and apoptosis, thus rescuing diabetic cardiomyopathy. We identified myeloid cell leukemia 1 (Mcl-1) as a major target gene for miR-340-5p and showed that the inhibition of Mcl-1 was responsible for increased functional loss of mitochondria, oxidative stress, and cardiomyocyte apoptosis, thereby caused cardiac dysfunction in diabetic mice. In conclusion, our results showed that miR-340-5p plays a crucial role in the development of DCM and can be targeted for therapeutic intervention.

show abstract

Section: Introductionmentioning

confidence: 99%

miR-340-5p Mediates Cardiomyocyte Oxidative Stress in Diabetes-Induced Cardiac Dysfunction by Targeting Mcl-1

Zhu

Yang

Zhou

et al. 2022

Oxidative Medicine and Cellular Longevity

View full text Add to dashboard Cite

show abstract

“…Given the specificity of expression of lncRNAs, it would be careless to think that the dysregulation of the expression of these molecules in cardiac pathological processes, even if the molecular mechanism behind them is not exactly understood, was a mere coincidence [69]. The poor conservation of these interspecies transcripts, however, makes it difficult to translate findings in rodent models for human applications; however, several studies have shown promising results regarding the prognosis of CVDs and new therapies from the modulation of cardiac lncRNAs [33,34,70,89,90,172,173]. We summarize the lncRNAs and the CVDs (Figure 2).…”

Section: Lncrnas In Cardiovascular Diseasesmentioning

confidence: 99%

“…Considering all of the above regarding the regulatory role of lncRNAs in the cardiovascular system and the observation that the dysregulation of the expression of these transcripts has been observed in CVDs, it seems appropriate to consider them as molecular targets in therapies [173,[203][204][205]. Through counter-regulation, the restoration of physiological expression levels of lncRNAs can occur both through gain-of-function strategies (for those lncRNAs that are significantly impaired) and through loss-of-function strategies (for those overexpressed).…”

Section: Lncrnas As Biomarkers and Potential Therapeutic Targets For Cardiovascular Diseasesmentioning

confidence: 99%

Long Non-Coding RNAs in Cardiovascular Diseases: Potential Function as Biomarkers and Therapeutic Targets of Exercise Training

Correia

Rodrigues

Pelozin

et al. 2021

ncRNA

View full text Add to dashboard Cite

Despite advances in treatments and therapies, cardiovascular diseases (CVDs) remain one of the leading causes of death worldwide. The discovery that most of the human genome, although transcribed, does not encode proteins was crucial for focusing on the potential of long non-coding RNAs (lncRNAs) as essential regulators of cell function at the epigenetic, transcriptional, and post-transcriptional levels. This class of non-coding RNAs is related to the pathophysiology of the cardiovascular system. The different expression profiles of lncRNAs, in different contexts of CVDs, change a great potential in their use as a biomarker and targets of therapeutic intervention. Furthermore, regular physical exercise plays a protective role against CVDs; on the other hand, little is known about its underlying molecular mechanisms. In this review, we look at the accumulated knowledge on lncRNAs and their functions in the cardiovascular system, focusing on the cardiovascular pathology of arterial hypertension, coronary heart disease, acute myocardial infarction, and heart failure. We discuss the potential of these molecules as biomarkers for clinical use, their limitations, and how the manipulation of the expression profile of these transcripts through physical exercise can begin to be suggested as a strategy for the treatment of CVDs.

show abstract

“…They participate in many physiological and pathophysiological processes such as: the regulation of signaling platelet pathways, gene regulation of eukaryotes, angiogenesis, and insulin secretion [37][38][39][40]. MiRNAs are considered targets for personifying intervention and translational therapy [41]. Under pathological conditions, cells can usually passively or actively deliver mi-croRNAs into circulation.…”

Section: Mirnas Superfamilymentioning

confidence: 99%

Current Knowledge of MicroRNAs (miRNAs) in Acute Coronary Syndrome (ACS): ST-Elevation Myocardial Infarction (STEMI)

Gosav

Ouatu

Bădescu

et al. 2021

Life

View full text Add to dashboard Cite

Regardless of the newly diagnostic and therapeutic advances, coronary artery disease (CAD) and more explicitly, ST-elevation myocardial infarction (STEMI), remains one of the leading causes of morbidity and mortality worldwide. Thus, early and prompt diagnosis of cardiac dysfunction is pivotal in STEMI patients for a better prognosis and outcome. In recent years, microRNAs (miRNAs) gained attention as potential biomarkers in myocardial infarction (MI) and acute coronary syndromes (ACS), as they have key roles in heart development, various cardiac processes, and act as indicators of cardiac damage. In this review, we describe the current available knowledge about cardiac miRNAs and their functions, and focus mainly on their potential use as novel circulating diagnostic and prognostic biomarkers in STEMI.

show abstract

Regulation of Long Non-coding RNAs and MicroRNAs in Heart Disease: Insight Into Mechanisms and Therapeutic Approaches

Cited by 24 publications

References 182 publications

miR-340-5p Mediates Cardiomyocyte Oxidative Stress in Diabetes-Induced Cardiac Dysfunction by Targeting Mcl-1

miR-340-5p Mediates Cardiomyocyte Oxidative Stress in Diabetes-Induced Cardiac Dysfunction by Targeting Mcl-1

Long Non-Coding RNAs in Cardiovascular Diseases: Potential Function as Biomarkers and Therapeutic Targets of Exercise Training

Current Knowledge of MicroRNAs (miRNAs) in Acute Coronary Syndrome (ACS): ST-Elevation Myocardial Infarction (STEMI)

Contact Info

Product

Resources

About